Last reviewed · How we verify

NCT07023887: EXERT-BCHC

Prospective Study of EXErcise Regimens After Treatment for Breast Cancer for Hypertrophy and Conditioning

Recruiting now Last updated 4 February 2026
What this trial tests

trial testing 6-12-25 Training Regimen in Cancer in 15 participants. Currently enrolling.

Timeline
21 May 2025
Primary endpoint
15 July 2026
15 October 2026

Quick facts

Lead sponsorAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment15
Start date21 May 2025
Primary completion15 July 2026
Estimated completion15 October 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Who can join

Adults 20 to 89, female only, with Cancer or Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study investigates the impact of four standard of care, monitored group exercise regimens (resistance training) on conditioning and hypertrophy in women previously treated for breast cancer. The study will compare two conditioning regimens (6-12-25 and 8x8) and two hypertrophy regimens (5/5/5 cluster sets and double training) to assess changes in VO2 max, muscle mass, and fat mass.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07023887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing